Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

If you are wondering whether Bristol-Myers Squibb is offering good value right now, this article will walk through what the ...

Bristol Myers BMY is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line ...

IHE has an attractive mix of high-growth stocks and cheaply valued ones. Click here to find out why IHE stock is a Buy.

Nationwide BNY Mellon Dynamic U.S. Equity Income Fund returned 4.54% in Q4 2025, outperforming its value index. Read the full analysis for more details.

Bloomsbury Publishing PLC (LSE:BMY) shares rose 17% to 557p on Thursday after the company announced that Sarah J. Maas will ...

When you get as many things going wrong as there are right now, you do not think about opportunity; you think about safety. I get that. We have the most uncertain of times in the Mideast after the U.S ...

Prothena Corporation (NASDAQ:PRTA) shares rose 4.7% in after-hours trading Friday after the biotechnology company announced a share repurchase program authorizing ...

Jim Cramer spotlighted the "Fourth Industrial Revolution" winners in the Club's portfolio during Friday's Monthly Meeting.

According to TipRanks.com, Schott is a 4-star analyst with an average return of 6.6% and a 57.6% success rate. Schott covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals, ...

Topline data of investigator-initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response ...